A Study Of The Effect Of CE-224535 On Knee OA (Osteoarthritis) Pain
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00418782. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 2 Week, Randomized, Double Blind, Placebo And Positive Controlled, Parallel Group, Multicenter Study Of CE-224,535 In Subjects With Osteoarthritic Pain Of The Knee
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
CE-224535 is a new medication being developed as an analgesic and anti-inflammatory agent for the treatment of the signs and symptoms of osteoarthritis (OA). The purpose of this study is to evaluate the analgesic and anti inflammatory efficacy and safety of CE 224,535 versus placebo and naproxen treatment in patients with OA knee pain.
Study identification
- NCT ID
- NCT00418782
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 212 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2007 (Type not available)
- Primary completion
- Not listed
- Completion
- Aug 2007 (Actual)
- Last update posted
- Dec 5, 2018
2007
United States locations
- U.S. sites
- 46
- U.S. states
- 21
- U.S. cities
- 42
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Anniston | Alabama | 36207 | — |
| Pfizer Investigational Site | Bayou La Batre | Alabama | 36509 | — |
| Pfizer Investigational Site | Birmingham | Alabama | 35209 | — |
| Pfizer Investigational Site | Birmingham | Alabama | 35216 | — |
| Pfizer Investigational Site | Birmingham | Alabama | 35242 | — |
| Pfizer Investigational Site | Hot Springs | Arkansas | 71913 | — |
| Pfizer Investigational Site | Northridge | California | 91325 | — |
| Pfizer Investigational Site | Sacramento | California | 95825 | — |
| Pfizer Investigational Site | Tarzana | California | 91356 | — |
| Pfizer Investigational Site | Denver | Colorado | 80204 | — |
| Pfizer Investigational Site | Denver | Colorado | 80206 | — |
| Pfizer Investigational Site | Westminster | Colorado | 80030 | — |
| Pfizer Investigational Site | Clearwater | Florida | 33761 | — |
| Pfizer Investigational Site | DeFuniak Springs | Florida | 32435 | — |
| Pfizer Investigational Site | Destin | Florida | 32541 | — |
| Pfizer Investigational Site | Pensacola | Florida | 32503 | — |
| Pfizer Investigational Site | Chicago | Illinois | 60053 | — |
| Pfizer Investigational Site | Gurnee | Illinois | 60031 | — |
| Pfizer Investigational Site | Avon | Indiana | 46123 | — |
| Pfizer Investigational Site | Indianapolis | Indiana | 46250 | — |
| Pfizer Investigational Site | Gretna | Louisiana | 70056 | — |
| Pfizer Investigational Site | Kenner | Louisiana | 70065 | — |
| Pfizer Investigational Site | Metairie | Louisiana | 70002 | — |
| Pfizer Investigational Site | Baltimore | Maryland | 21218 | — |
| Pfizer Investigational Site | Frederick | Maryland | 21702 | — |
| Pfizer Investigational Site | Flowood | Mississippi | 39232 | — |
| Pfizer Investigational Site | Columbia | Missouri | 65212 | — |
| Pfizer Investigational Site | Kansas City | Missouri | 64114 | — |
| Pfizer Investigational Site | Missoula | Montana | 59802 | — |
| Pfizer Investigational Site | Trenton | New Jersey | 08611 | — |
| Pfizer Investigational Site | Beavercreek | Ohio | 45440 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45242 | — |
| Pfizer Investigational Site | Kettering | Ohio | 45429 | — |
| Pfizer Investigational Site | Ashland | Oregon | 97520 | — |
| Pfizer Investigational Site | Eugene | Oregon | 97404 | — |
| Pfizer Investigational Site | Duncansville | Pennsylvania | 16635 | — |
| Pfizer Investigational Site | Summerville | South Carolina | 29485 | — |
| Pfizer Investigational Site | Collierville | Tennessee | 38017 | — |
| Pfizer Investigational Site | Knoxville | Tennessee | 37909-1900 | — |
| Pfizer Investigational Site | Memphis | Tennessee | 38104 | — |
| Pfizer Investigational Site | Bryan | Texas | 77802 | — |
| Pfizer Investigational Site | Longview | Texas | 75605 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78213 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78229 | — |
| Pfizer Investigational Site | Arlington | Virginia | 22205 | — |
| Pfizer Investigational Site | Spokane | Washington | 99216 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00418782, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 5, 2018 · Synced Nov 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.